https://www.rethink1let.com
赞助Endocrine Resistance Affects Patients' Time On 1st Line Treatment For HR+ mBC Patients. In HR+ mBC, Tumors May Become Endocrine Resistant Upon Exposure To 1L Treatment.
Types: Endocrine Therapy, Estrogen Therapy, HR+/HER2- mBC, ESR1 Mutation